Dry Eye Syndrome Therapeutics Pipeline Analysis, 2017 – Clinical Trials & Results, Collaboration and Other Developments

The study analyzed that the dry eye syndrome therapeutics pipeline comprises approximately 50 drug candidates in different stages of development.

According to the research findings, most of the drug candidates of dry eye syndrome pipeline are being developed to be administered by topical route.

Explore Report Description at: https://www.psmarketresearch.com/market-analysis/dry-eye-syndrome-therapeutics-pipeline-analysis

InSite Vision (A Sun Pharmaceutical Industries Ltd. company) is using DuraSite technology platform for the development of their drug candidates for the treatment of dry eye syndrome. DuraSite is a drug delivery vehicle that stabilizes small molecules in a polymeric mucoadhesive matrix.

The research found that various companies use natural sources for the development of dry eye syndrome therapeutics pipeline that includes, but not limited to, MC2 Therapeutics and RegeneRx Biopharmaceuticals, Inc.

Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/dry-eye-syndrome-therapeutics-pipeline-analysis/report-sample

Some of the other key players developing drugs for the treatment of dry eye syndrome include Ocular Therapeutix, Inc., LTT Bio-Pharma, HanAll BioPharma Co., Ltd. and others.

Designed by CyFocus.com
Powered by CyFocus.net